The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Tumor-Infiltrating Lymphocyte Grade in Primary Melanomas Is Independently Associated With Melanoma-Specific Survival in the Population-Based Genes, Environment and Melanoma Study
Open accessAbstract
Purpose: Although most hospital-based studies suggest more favorable survival with tumor-infiltrating lymphocytes (TILs) present in primary melanomas, it is uncertain whether TILs provide prognostic information beyond existing melanoma staging definitions. We addressed the issue in an international population-based study of patients with single and multiple primary melanomas. Patients and Methods: On the basis of the Genes, Environment and Melanoma (GEM) study, we conducted follow-up of 2,845 patients diagnosed from 1998 to 2003 with 3,330 invasive primary melanomas centrally reviewed for TIL grade (absent, nonbrisk, or brisk). The odds of TIL grades associated with clinicopathologic features and survival by TIL grade were examined. Results: Independent predictors (P < .05) for nonbrisk TIL grade were site, histologic subtype, and Breslow thickness, and for brisk TIL grade, they were age, site, Breslow thickness, and radial growth phase. Nonbrisk and brisk TIL grades were each associated with lower American Joint Committee on Cancer (AJCC) tumor stage compared with TIL absence (P trend < .001). Death as a result of melanoma was 30% less with nonbrisk TIL grade (hazard ratio [HR], 0.7; 95% CI, 0.5 to 1.0) and 50% less with brisk TIL grade (HR, 0.5; 95% CI, 0.3 to 0.9) relative to TIL absence, adjusted for age, sex, site, and AJCC tumor stage. Conclusion: At the population level, higher TIL grade of primary melanoma is associated with a lower risk of death as a result of melanoma independently of tumor characteristics currently used for AJCC tumor stage. We conclude that TIL grade deserves further prospective investigation to determine whether it should be included in future AJCC staging revisions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Final Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,602
Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157
The histogenesis and biologic behavior of primary human malignant melanomas of the skin.
Clark, W. H., From, L., Bernardino, E. A., & Mihm, M. C. (1969) · PubMed · Cited by 2,112
Self-citationModel Predicting Survival in Stage I Melanoma Based on Tumor Progression
Clark, W. H., Elder, D. E., Guerry, D., Braitman, L. E., Trock, B. J., Schultz, D., Synnestvedt, M., & Halpern, A. C. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.24.1893 · Cited by 1,247
Clemente, C. G., Mihm, M. C., Bufalino, R., Zurrida, S., Collini, P., & Cascinelli, N. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960401)77:7<1303::aid-cncr12>3.0.co;2-5 · Cited by 1,171
Azimi, F., Scolyer, R. A., Rumcheva, P., Moncrieff, M., Murali, R., McCarthy, S. W., Saw, R. P., & Thompson, J. F. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.8539 · Cited by 856
Statistical Analysis of Epidemiologic Data
Selvin, S. (2004) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195172805.001.0001 · Cited by 822
An immune-active tumor microenvironment favors clinical response to ipilimumab
Ji, R.-R., Chasalow, S. D., Wang, L., Hamid, O., Schmidt, H., Cogswell, J., Alaparthy, S., Berman, D., Jure-Kunkel, M., Siemers, N. O., et al. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1172-6 · Cited by 775
The classification of malignant melanoma and its histologic reporting
McGovern, V. J., Mihm, M. C., Bailly, C., Booth, J. C., Clark, W. H., Cochran, A. J., Hardy, E. G., Hicks, J. D., Levene, A., Lewis, M. G., et al. (1973) · Cancer · doi:10.1002/1097-0142(197312)32:6<1446::aid-cncr2820320623>3.0.co;2-8 · Cited by 443
Gomez, C. R., Nomellini, V., Faunce, D. E., & Kovacs, E. J. (2008) · Experimental Gerontology · doi:10.1016/j.exger.2008.05.016 · Cited by 328
Edlundh-Rose, E., Egyha??zi, S., Omholt, K., Mansson-Brahme, E., Platz, A., Hansson, J., & Lundeberg, J. (2006) · Melanoma Research · doi:10.1097/01.cmr.0000232300.22032.86 · Cited by 318
Taylor, R. C., Patel, A., Panageas, K. S., Busam, K. J., & Brady, M. S. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.9755 · Cited by 297
Self-citationPredicting five-year outcome for patients with cutaneous melanoma in a population-based study
Barnhill, R. L., Fine, J. A., Roush, G. C., & Berwick, M. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960801)78:3<427::aid-cncr8>3.0.co;2-g · Cited by 296
Self-citationJensen, T. O., Schmidt, H., Møller, H. J., Donskov, F., Høyer, M., Sjoegren, P., Christensen, I. J., & Steiniche, T. (2012) · Cancer · doi:10.1002/cncr.26511 · Cited by 281
Lachiewicz, A. M., Berwick, M., Wiggins, C. L., & Thomas, N. E. (2008) · Archives of Dermatology · doi:10.1001/archderm.144.4.515 · Cited by 264
Self-citationGajewski, T. F., Louahed, J., & Brichard, V. G. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181eacbd8 · Cited by 250
Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma.
Oble, D. A., Loewe, R. P., Yu, P., & Mihm, M. C. (2009) · PubMed · Cited by 237
Green, A. C., Baade, P., Coory, M., Aitken, J. F., & Smithers, M. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.8561 · Cited by 206
van Houdt, I. S., Sluijter, B. J. R., Moesbergen, L. M., Vos, W., de Gruijl, T. D., Molenkamp, B. G., van den Eertwegh, A. J. M., Hooijberg, E., van Leeuwen, P. A. M., Meijer, C. J. L. M., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23543 · Cited by 138
Risk Assessment in Localized Primary Cutaneous Melanoma
Tuthill, R. J., Unger, J. M., Liu, P. Y., Flaherty, L. E., & Sondak, V. K. (2002) · American Journal of Clinical Pathology · doi:10.1309/wbf7-n8kh-71kt-rvq9 · Cited by 108
Millikan, R. C., Hummer, A., Begg, C. B., Player, J., de Cotret, A. R., Winkel, S., Mohrenweiser, H. W., Thomas, N. E., Armstrong, B. K., Kricker, A., et al. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi252 · Cited by 98
Self-citationMandalà, M., Imberti, G. L., Piazzalunga, D., Belfiglio, M., Labianca, R., Barberis, M. C. P., Marchesi, L., Poletti, P. L., Bonomi, L., Novellino, L., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.05.034 · Cited by 92
Histologic Classification of Tumor-Infiltrating Lymphocytes in Primary Cutaneous Malignant Melanoma
BUSAM, K. J., Antonescu, C. R., Marghoob, A. A., Nehal, K. S., Sachs, D. L., Shia, J., & Berwick, M. (2001) · American Journal of Clinical Pathology · doi:10.1309/g6ek-y6eh-0lgy-6d6p · Cited by 89
Self-citationBegg, C. B., Hummer, A., Mujumdar, U., Armstrong, B. K., Kricker, A., Marrett, L. D., Millikan, R. C., Gruber, S. B., Culver, H. A., Zanetti, R., et al. (2006) · International Journal of Epidemiology · doi:10.1093/ije/dyl044 · Cited by 71
Self-citationRao, U. N. M., Lee, S. J., Luo, W., Mihm, M. C., & Kirkwood, J. M. (2010) · American Journal of Clinical Pathology · doi:10.1309/ajcptxmefovywda6 · Cited by 56
Familial aggregation of melanoma risks in a large population-based sample of melanoma cases
Begg, C. B., Hummer, A., Mujumdar, U., Armstrong, B. K., Kricker, A., Marrett, L. D., Millikan, R. C., Gruber, S. B., Anton‐Culver, H., Klotz, J. B., et al. (2004) · Cancer Causes & Control · doi:10.1007/s10522-004-2474-2 · Cited by 54
Self-citation
Cited by
Taube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Gibney, G. T., Weiner, L. M., & Atkins, M. B. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30406-5 · Cited by 1,635
Tumour-intrinsic resistance to immune checkpoint blockade
Kalbasi, A., & Ribas, A. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0218-4 · Cited by 1,486
Targeted agents and immunotherapies: optimizing outcomes in melanoma
Luke, J. J., Flaherty, K. T., Ribas, A., & Long, G. V. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.43 · Cited by 1,254
Hendry, S., Salgado, R., Gevaert, T., Russell, P. A., John, T., Thapa, B., Christie, M., van de Vijver, K., Estrada, M. V., Gonzalez-Ericsson, P. I., et al. (2017) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000161 · Cited by 799
Metadata
- Authors
- Thomas, N. E., Busam, K. J., From, L., Kricker, A., Armstrong, B. K., Anton-Culver, H., Gruber, S. B., Gallagher, R. P., Zanetti, R., Rosso, S., Dwyer, T., Venn, A., Kanetsky, P. A., Groben, P. A., Hao, H., Orlow, I., Reiner, A. S., Luo, L., Paine, S., Ollila, D. W., Wilcox, H., Begg, C. B., & Berwick, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-11-20
- Volume
- 31
- Issue
- 33
- Pages
- 4252-4259
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2118342755
- Cited by
- 284
- References
- 28
- FWCI
- 8.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.